CRISPR-Cas9-modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazine-containing compounds but potentiates artemisinin-based combination therapy partner drugs

Emerging resistance to first-line antimalarial combination therapies threatens malaria treatment and the global elimination campaign. Improved therapeutic strategies are required to protect existing drugs and enhance treatment efficacy. We report that the piperazine-containing compound ACT-451840 ex...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Microbiol
Auteurs principaux: Ng, Caroline L., Siciliano, Giulia, Lee, Marcus C. S., de Almeida, Mariana J., Corey, Victoria C., Bopp, Selina E., Bertuccini, Lucia, Wittlin, Sergio, Kasdin, Rachel G., Le Bihan, Amélie, Clozel, Martine, Winzeler, Elizabeth A., Alano, Pietro, Fidock, David A.
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4958522/
https://ncbi.nlm.nih.gov/pubmed/27073104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/mmi.13397
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires